PROF 8-K: Ceo change

Profound Medical

Filed with the SEC on · accession 0001171843-26-007182

PROF filed a 8-K (current report) with the SEC on Nov 5, 2026. Profound Medical reported strong Q3 2026 results with revenue up 86% year-over-year to $9.8 million and gross margin of 78%, while announcing CEO succession with Richard Fabian appointed as CEO effective January 14, 2027, Arun Menawat transitioning to Executive Chairman, Matthew Sobczyk becoming… The stock moved -3.9% by the first close after the filing.

Summary of the filing

Profound Medical reported strong Q3 2026 results with revenue up 86% year-over-year to $9.8 million and gross margin of 78%, while announcing CEO succession with Richard Fabian appointed as CEO effective January 14, 2027, Arun Menawat transitioning to Executive Chairman, Matthew Sobczyk becoming permanent CFO, and Jason Mills joining the Board. The company also entered a new U.S. distribution agreement with Cook Medical and reaffirmed full-year 2026 revenue guidance of at least $25.0 million.

Key details

Q3 2026 total revenue$9.8M
Q3 2026 recurring non-capital revenue$4.1M
Q3 2026 capital equipment sales$5.7M
Q3 2026 operating expenses$15.5M
Q3 2026 cash used in operating activities$5.0M
Q2 2026 cash used in operating activities$11.3M
Q3 2025 cash used in operating activities$9.6M
Q3 2026 net loss$7.7M
Q3 2025 net loss$8.0M
Cash at September 30, 2026$33.3M
Full-year 2026 revenue guidance (minimum)$25.0M
Qualified sales pipeline at end of Q3 2026$79.2M
IssuerProfound Medical Corp.
Distribution partnerCook Medical
Co-sales and co-marketing partnerSiemens Healthineers
CeoRichard Fabian
Executive chairmanArun Menawat
CfoMatthew Sobczyk
Board memberJason Mills

How PROF stock reacted

Close before

$7.16

Nov 4, 2026

First close after

-3.91%

$6.88

5 trading days

—

Since filing

-6.15%

$6.72

✦ Ask GOAX AI about this filing — what it means for PROF, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PROF?

Click here

Frequently asked questions

What did PROF file with the SEC on Nov 5, 2026?

PROF filed a 8-K (Ceo change). Profound Medical reported strong Q3 2026 results with revenue up 86% year-over-year to $9.8 million and gross margin of 78%, while announcing CEO succession with Richard Fabian appointed as CEO effective January 14, 2027, Arun Menawat transitioning to Executive Chairman, Matthew Sobczyk becoming permanent CFO, and Jason Mills joining the Board. The company also entered a new U.S. distribution agreement with Cook Medical and reaffirmed full-year 2026 revenue guidance of at least $25.0 million.

What does a ceo change mean for PROF stock?

Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did PROF stock react to this filing?

PROF closed at $7.16 before the filing and $6.88 on Nov 5, 2026 (-3.91%).

Other PROF SEC filings

Get alerts when PROF files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days